Analysts Are Bullish on These Healthcare Stocks: Progyny (PGNY), Ionis Pharmaceuticals (IONS)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Progyny (PGNY – Research Report) and Ionis Pharmaceuticals (IONS – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Progyny (PGNY)
Bank of America Securities analyst Allen Lutz maintained a Buy rating on Progyny on January 16 and set a price target of $30.00. The company’s shares closed last Friday at $24.52.
According to TipRanks.com, Lutz is a 5-star analyst with an average return of
Currently, the analyst consensus on Progyny is a Strong Buy with an average price target of $29.14, a 20.0% upside from current levels. In a report issued on January 8, Truist Financial also upgraded the stock to Buy with a $34.00 price target.
See today’s best-performing stocks on TipRanks >>
Ionis Pharmaceuticals (IONS)
In a report issued on January 17, Matt Phipps from William Blair reiterated a Buy rating on Ionis Pharmaceuticals. The company’s shares closed last Friday at $76.33.
According to TipRanks.com, Phipps is a 4-star analyst with an average return of
Ionis Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $94.92, a 23.0% upside from current levels. In a report issued on January 7, TipRanks – Google also upgraded the stock to Buy with a $95.00 price target.
